February 1, 2019

February 01, 2019

How the Moffitt Cancer Center plans to bring artificial intelligence to healthcare

Tampa Bay Innovation – Jan. 31

Imagine being alerted that you are going to have an adverse reaction to medicine prior to taking it, or being recommended for a clinical trial before experiencing any symptoms. These are just some of the health-related insights that can be gathered from data collection through artificial intelligence, which the Moffitt Cancer Center is working toward with its latest hire.

 

Critics pour water on scientists' claim of a cure for cancer within the next year

Yahoo News UK – Jan. 30

Dr Vince Luca, assistant professor of Cancer Biology at Moffitt Cancer Centre, echoed the concerns, saying that ‘very few peptide-based drugs have received FDA approval for oncology indications’.

 

Moffitt researchers say 'cure for cancer' claim is full of red flags

WTSP – Jan. 30

Researchers at Moffitt Cancer Center in Tampa said the "cure for cancer" from Israeli doctors hasn't been peer-reviewed or tested.

 

The Role Of BRAF Mutations In Treatment Of Cholangiocarcinoma

Oncology Tube – Jan. 30

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses The Role Of BRAF Mutations In Treatment Of Cholangiocarcinoma. 

 

Gastrectomy does not alter benefit of new oral chemo in gastric cancer

MD Edge – Jan. 30

The disconnect between toxicity and treatment discontinuation seen in the TAGS trial is not new, according to invited discussant Martine Extermann, MD, PhD, leader of the Senior Adult Oncology Program at the Moffitt Cancer Center in Tampa.

 

Virus injection into tumor may treat metastatic melanoma 

Specialty Medical Dialogues – Jan. 30

Jonathan S. Zager, MD, FACS, of Moffitt Cancer Center, Tampa, Fla., and Keith A. Delman, MD, FACS, of Emory University School of Medicine, Atlanta, Ga., directed the study at their centers and are lead coauthors with Dr. Ollila.

 

Moffitt Cancer Center Names AIO (Artificial Intelligence Officer)

Healthcare Innovation – Jan. 29

It’s obvious that data science is playing an increasingly important role in healthcare settings. But is it time to name an AIO or “artificial intelligence officer” for your health system? Tampa, Fla.-based Moffitt Cancer Center thinks so. It has hired J. Ross Mitchell, Ph.D., as its first AIO.

 

Will we have a cure for cancer within a year? Israeli scientists claim they've found the Holy Grail - but critics warn their findings are thin and we will probably NEVER have one single cure

Daily Mail – Jan. 29

That is not enough to warrant excitement or even intrigue, says Dr. Vince Luca, assistant professor of Cancer Biology at Moffitt Cancer Center. 'Peptides are a rapidly growing class of therapeutics, yet very few peptide-based drugs have received FDA approval for oncology indications,' Dr. Luca told DailyMail.com.

 

Moffitt reacts with skepticism to Israeli company's claim of cancer 'cure'

WTVT – Jan. 29

"It is not really fair for them to announce something like this without really properly vetting it, without peer-reviewed publications or with a clinical trial," said Moffitt Cancer Center researcher Vince Luca.

 

Verify: A cancer ‘cure’ within a year?

WTSP – Jan. 29

A researcher at Moffitt Cancer Center cautions the claims of Israeli scientists are slim and a single cure-all for cancer will likely never exist.

 

Accelerated Chemo Regimen Extends OS in Neoadjuvant Bladder Cancer Treatment

Oncology Nursing News – Jan. 29

The investigators, led by Charles C. Peyton, MD, a urologic oncology fellow at Moffitt Cancer Center, performed a retrospective analysis of 1113 patients who underwent cystectomy for bladder cancer at the Moffitt Cancer Center in Tampa, Florida to compare neoadjuvant chemotherapy regimens.

 

Guide for HER2 Testing That's Not 'by Eye'

Medscape – Jan. 28

Guideline lead author Marilyn Bui, MD, PhD, Moffitt Cancer Center, Tampa, Florida, explained the importance of the new automated technology. "QIA has been shown to improve consistency and accuracy of interpretation among pathologists," she said.

 

Moffitt Cancer Center turns to artificial intelligence with new hire

Tampa Bay Business Journal – Jan. 28

The technology industry is not the only sector clamoring to work with artificial intelligence. Moffitt Cancer Center in Tampa is looking to get further involved, and has hired an artificial intelligence officer.

 

Modified herpes virus effective against late-stage melanoma

Medical News Today – Jan. 26

Recently, a team of researchers from the University of North Carolina at Chapel Hill, the Moffitt Cancer Center in Tampa, FL, and Emory University in Atlanta, GA, studied the effects of TVEC treatment in 80 people with late-stage melanoma who had received this therapy for over 3 years.

 

New Pathology Guideline Advances Accuracy in Breast Cancer Testing

Imaging Technology News – Jan. 25

"We set out to bridge the gap between technology and clinical practice with recommendations based on expert review of published literature," said project chair Marilyn M. Bui, M.D., Ph.D., FCAP, of the Moffitt Cancer Center, Tampa, Fla. 

 

Genetically modified virus injection into tumor can treat metastatic melanoma

Medical Xpress – Jan. 25

Jonathan S. Zager, MD, FACS, of Moffitt Cancer Center, Tampa, Fla., and Keith A. Delman, MD, FACS, of Emory University School of Medicine, Atlanta, Ga., directed the study at their centers and are lead coauthors with Dr. Ollila.

 

Mantle Cell Lymphoma: An Overview of Therapy

OncLive – Jan. 25

Insights From: Bijal D. Shah, MD, H. Lee Moffitt Cancer Center & Research Institute; Lauren C. Pinter-Brown, MD, UCI Health; Eduardo Sotomayor, MD, GW Cancer Center

 

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.